Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-159-0 | CAS number: 78-93-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
In accordance with Regulation (EC) No 1907/2006 Annex VIII section 8.8.1, a toxicokinetics study is not required as assessment of the toxicokinetic behaviour of the substance has been derived from the relevant available information. This assessment is located within the endpoint summary for toxicokinetics, metabolism and distribution.
Key value for chemical safety assessment
- Absorption rate - dermal (%):
- 4
- Absorption rate - inhalation (%):
- 54
Additional information
Considering the physicochemical properties of MEK, [i.e. low molecular weight (72.11 g/mol), low log Kow value (0.3), and vapor pressure of 12.6 kPa at 25°C], absorption of MEK from various routes of exposure, such as oral, dermal or inhalation is expected. However, absorption of MEK is expected to mainly occur via oral and inhalation routes, with limited potential for dermal absorption.
The metabolic fate of MEK has been reported to include both oxidative and reductive pathways, with the latter leading to the production of secondary butyl alcohol, sBA). The oxidative pathway involves MEK oxidation catalyzed by liver microsomal mixed-function oxidases to form 3-hydroxy-2-butanone, which is subsequently reduced to 2,3-butanediol. The hydroxylation product of MEK, 3-hydroxy-2-butanone is expected either to undergo conjugation with sulfate or glucuronic acid and elimination of the conjugated metabolites in the urine, or to enter intermediary metabolism to form carbon dioxide. Taking into consideration the low molecular weight and log P, and its considerable water solubility, MEK is not expected to bioaccumulate.
Additional information on the toxicokinetics of read-across substances, secondary butanol (sBA) and methyl isobutyl ketone (MIBK) is also included to support the read-across justification.
Animal data show that secondary butanol (sBA) is absorbed, distributed and excreted rapidly in urine, mainly as MEK, following oral administration. A small percentage of sBA is also excreted via urine and exhalation. Orally administered sBA is metabolized via alcohol hydrogenase to MEK. The maximum concentration of MEK in blood was seen six hours after dosing. Further oxidation of MEK appeared to proceed by hydroxylation of the omega-1 carbon to form 3-hydroxy-2-butanone, which is further reduced to 2,3-butanediol. 2,3-Butanediol was also detected in human urine following inhalation exposure to MEK (Liira, 1988 and 1990). The main portion of the inhaled MEK is converted to acetate or acetoactate via 3-hydroxy-2-butanone intermediate metabolite. Following absorption, MEK is anticipated to be distributed evenly throughout the body. The pharmacokinetic data available for sBA demonstrate that it may be used as a surrogate for MEK considering that sBA is rapidly metabolized to MEK, and that the two share common metabolites (3-hydroxy-2-butanone and 2,3-butanediol).
Summary of absorption
Inhalation: 54% retention has been reported from inhalation exposures (Ibriani et al., 1989), which is in agreement with the results from human exposure (Liira, 1988 and 1990).
Oral: MEK has a molecular weight of <500 g/mol and a log Kow between 0 and 4; therefore, it is assumed to be well absorbed equivalently by the oral and inhalation route; therefore, oral assumed to be 54%.
Dermal: dermal absorption of MEK, in vivo, was reported to be 4% (NIOSH, 2002).
Summary of distribution
The solubilities of MEK in water, blood and oil are similar, with distribution coefficients reported to be 254 for water/air, 202 for blood/air and 263 for oil/air (Saida, 1976). These values suggest that MEK is distributed evenly in the soft tissues (Liira, 1988). Studies in humans show that, following inhalation exposure, MEK is retained in the blood, as shown by the low excretion of MEK in exhaled air (Liira, 1988).
Summary of metabolism
The main metabolites of MEK found in serum and urine after intraperitoneal administration to guinea pigs or inhalation exposure of humans were 3-hydroxy-2-butanone and 2, 3-butanediol (DiVincenzo et al, 1976).
The main metabolites of MIBK found in serum after intraperitoneal administration to guinea pigs were 4-methyl-2-pentanol and 4-hydroxy-4-methyl-2-pentanone. 4-hydroxy-4-methyl-2-pentanone was the principal metabolite (DiVincenzo et al, 1976).
Minimal qualitative and quantitative differences have been found between the metabolism of sBA and that of MEK (Dietz, 1981),
The metabolic pathways of MEK, sBA and MIBK have been established.
Summary of elimination
After inhalation exposure of humans, 2-3% of the absorbed dose is eliminated by exhalation, and the majority of the absorbed dose is eliminated in the urine as the metabolite sBA (Liira, 1988). Urinary excretion of parent MEK after inhalation exposure of humans has been shown to be very low, about 0.2% of the absorbed dose (Liira, 1990). After oral exposure in the form of gelatin (sic) capsules, pulmonary excretion is reported to be about 30% of the administered dose (Munies, 1965).
Please refer to the document attached to Section 13 for further discussion of toxicokinetics.
References
Imbriani, M., Ghittori, S., Pezzagno, G., & Capodaglio, E. (1989). Methyl ethyl ketone (MEK) in urine as biological index of exposure. Giornale italiano di medicina del lavoro, 11(6), 255-261.
NIOSH (2002) https://www.cdc.gov/niosh/docs/2003-154/pdfs/8319.pdf
Munies R, Wurster DE (1965) Investigation of some factors influencing percutaneous absorption III Absorption of methyl ethyl ketone J Pharmacol Sci 54:1281-1284, as cited in Liira, 1988.Saida K, Mendell JR, Weiss HS (1976) Peripheral nerve changes induced by methyl n-butyl ketone and potentiation by methyl ethyl ketone J Neuropathol Exp Neurol 35:207-225, as cited in Liira, 1988.
Discussion of human information
Human data show that uptake via the inhalation route is between 46% and 56%, and the ultimate metabolite of MEK excreted in the urine is secondary butanol (sBA) (Liira, 1988 and 1990).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.